Cargando…

Validation of microscopic observation drug susceptibility testing for rapid, direct rifampicin and isoniazid drug susceptibility testing in patients receiving tuberculosis treatment

Drug susceptibility testing (DST) is often needed in patients clinically failing tuberculosis (TB) therapy. Most studies of phenotypic direct drug susceptibility tests, such as microscopic observation drug susceptibility (MODS) tests, have been performed in patients not receiving TB treatment. The e...

Descripción completa

Detalles Bibliográficos
Autores principales: Coronel, J, Roper, M H, Herrera, C, Bonilla, C, Jave, O, Gianella, C, Sabogal, I, Huancaré, V, Leo, E, Tyas, A, Mendoza-Ticona, A, Caviedes, L, Moore, D A J, Drancourt, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302318/
https://www.ncbi.nlm.nih.gov/pubmed/24107197
http://dx.doi.org/10.1111/1469-0691.12401
_version_ 1782353777208066048
author Coronel, J
Roper, M H
Herrera, C
Bonilla, C
Jave, O
Gianella, C
Sabogal, I
Huancaré, V
Leo, E
Tyas, A
Mendoza-Ticona, A
Caviedes, L
Moore, D A J
Drancourt, M
author_facet Coronel, J
Roper, M H
Herrera, C
Bonilla, C
Jave, O
Gianella, C
Sabogal, I
Huancaré, V
Leo, E
Tyas, A
Mendoza-Ticona, A
Caviedes, L
Moore, D A J
Drancourt, M
author_sort Coronel, J
collection PubMed
description Drug susceptibility testing (DST) is often needed in patients clinically failing tuberculosis (TB) therapy. Most studies of phenotypic direct drug susceptibility tests, such as microscopic observation drug susceptibility (MODS) tests, have been performed in patients not receiving TB treatment. The effect of ongoing TB treatment on the performance of MODS direct DST has not been previously explored, but patients failing such therapy constitute an important target group. The aim of this study was to determine the performance of MODS direct rifampicin and isoniazid DST in patients clinically failing first-line TB treatment, and to compare MODS direct DST with indirect proportion method DST. Sputa from 264 TB patients were cultured in parallel in Lowenstein–Jensen (LJ) and MODS assays; strains were tested for rifampicin and isoniazid susceptibility by the proportion method at the national reference laboratory. Ninety-three samples were culture-positive by LJ and MODS (concordance of 96%; kappa 0.92). With conventional MODS plate DST reading (performed on the same day as the sample is classified as culture-positive), the isoniazid DST concordance was 96.8% (kappa 0.89), and the concordance for rifampicin susceptibility testing was 92.6% (kappa 0.80). Reading of MODS DST plates 1 week after cultures had been determined to be culture-positive improved overall performance marginally—the isoniazid DST concordance was 95.7% (kappa 0.85); and the rifampicin DST concordance was 96.8% (kappa 0.91). Sensitivity for detection of multidrug-resistant TB was 95.8%. MODS testing provided reliable rifampicin and isoniazid DST results for samples obtained from patients receiving TB therapy. A modified DST reading schedule for such samples, with a final reading 1 week after a MODS culture turns positive, marginally improves the concordance with reference DST.
format Online
Article
Text
id pubmed-4302318
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-43023182015-01-29 Validation of microscopic observation drug susceptibility testing for rapid, direct rifampicin and isoniazid drug susceptibility testing in patients receiving tuberculosis treatment Coronel, J Roper, M H Herrera, C Bonilla, C Jave, O Gianella, C Sabogal, I Huancaré, V Leo, E Tyas, A Mendoza-Ticona, A Caviedes, L Moore, D A J Drancourt, M Clin Microbiol Infect Bacteriology Drug susceptibility testing (DST) is often needed in patients clinically failing tuberculosis (TB) therapy. Most studies of phenotypic direct drug susceptibility tests, such as microscopic observation drug susceptibility (MODS) tests, have been performed in patients not receiving TB treatment. The effect of ongoing TB treatment on the performance of MODS direct DST has not been previously explored, but patients failing such therapy constitute an important target group. The aim of this study was to determine the performance of MODS direct rifampicin and isoniazid DST in patients clinically failing first-line TB treatment, and to compare MODS direct DST with indirect proportion method DST. Sputa from 264 TB patients were cultured in parallel in Lowenstein–Jensen (LJ) and MODS assays; strains were tested for rifampicin and isoniazid susceptibility by the proportion method at the national reference laboratory. Ninety-three samples were culture-positive by LJ and MODS (concordance of 96%; kappa 0.92). With conventional MODS plate DST reading (performed on the same day as the sample is classified as culture-positive), the isoniazid DST concordance was 96.8% (kappa 0.89), and the concordance for rifampicin susceptibility testing was 92.6% (kappa 0.80). Reading of MODS DST plates 1 week after cultures had been determined to be culture-positive improved overall performance marginally—the isoniazid DST concordance was 95.7% (kappa 0.85); and the rifampicin DST concordance was 96.8% (kappa 0.91). Sensitivity for detection of multidrug-resistant TB was 95.8%. MODS testing provided reliable rifampicin and isoniazid DST results for samples obtained from patients receiving TB therapy. A modified DST reading schedule for such samples, with a final reading 1 week after a MODS culture turns positive, marginally improves the concordance with reference DST. BlackWell Publishing Ltd 2014-06 2013-11-21 /pmc/articles/PMC4302318/ /pubmed/24107197 http://dx.doi.org/10.1111/1469-0691.12401 Text en © 2013 The Authors Clinical Microbiology and Infection published by John Wiley & Sons Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Bacteriology
Coronel, J
Roper, M H
Herrera, C
Bonilla, C
Jave, O
Gianella, C
Sabogal, I
Huancaré, V
Leo, E
Tyas, A
Mendoza-Ticona, A
Caviedes, L
Moore, D A J
Drancourt, M
Validation of microscopic observation drug susceptibility testing for rapid, direct rifampicin and isoniazid drug susceptibility testing in patients receiving tuberculosis treatment
title Validation of microscopic observation drug susceptibility testing for rapid, direct rifampicin and isoniazid drug susceptibility testing in patients receiving tuberculosis treatment
title_full Validation of microscopic observation drug susceptibility testing for rapid, direct rifampicin and isoniazid drug susceptibility testing in patients receiving tuberculosis treatment
title_fullStr Validation of microscopic observation drug susceptibility testing for rapid, direct rifampicin and isoniazid drug susceptibility testing in patients receiving tuberculosis treatment
title_full_unstemmed Validation of microscopic observation drug susceptibility testing for rapid, direct rifampicin and isoniazid drug susceptibility testing in patients receiving tuberculosis treatment
title_short Validation of microscopic observation drug susceptibility testing for rapid, direct rifampicin and isoniazid drug susceptibility testing in patients receiving tuberculosis treatment
title_sort validation of microscopic observation drug susceptibility testing for rapid, direct rifampicin and isoniazid drug susceptibility testing in patients receiving tuberculosis treatment
topic Bacteriology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302318/
https://www.ncbi.nlm.nih.gov/pubmed/24107197
http://dx.doi.org/10.1111/1469-0691.12401
work_keys_str_mv AT coronelj validationofmicroscopicobservationdrugsusceptibilitytestingforrapiddirectrifampicinandisoniaziddrugsusceptibilitytestinginpatientsreceivingtuberculosistreatment
AT ropermh validationofmicroscopicobservationdrugsusceptibilitytestingforrapiddirectrifampicinandisoniaziddrugsusceptibilitytestinginpatientsreceivingtuberculosistreatment
AT herrerac validationofmicroscopicobservationdrugsusceptibilitytestingforrapiddirectrifampicinandisoniaziddrugsusceptibilitytestinginpatientsreceivingtuberculosistreatment
AT bonillac validationofmicroscopicobservationdrugsusceptibilitytestingforrapiddirectrifampicinandisoniaziddrugsusceptibilitytestinginpatientsreceivingtuberculosistreatment
AT javeo validationofmicroscopicobservationdrugsusceptibilitytestingforrapiddirectrifampicinandisoniaziddrugsusceptibilitytestinginpatientsreceivingtuberculosistreatment
AT gianellac validationofmicroscopicobservationdrugsusceptibilitytestingforrapiddirectrifampicinandisoniaziddrugsusceptibilitytestinginpatientsreceivingtuberculosistreatment
AT sabogali validationofmicroscopicobservationdrugsusceptibilitytestingforrapiddirectrifampicinandisoniaziddrugsusceptibilitytestinginpatientsreceivingtuberculosistreatment
AT huancarev validationofmicroscopicobservationdrugsusceptibilitytestingforrapiddirectrifampicinandisoniaziddrugsusceptibilitytestinginpatientsreceivingtuberculosistreatment
AT leoe validationofmicroscopicobservationdrugsusceptibilitytestingforrapiddirectrifampicinandisoniaziddrugsusceptibilitytestinginpatientsreceivingtuberculosistreatment
AT tyasa validationofmicroscopicobservationdrugsusceptibilitytestingforrapiddirectrifampicinandisoniaziddrugsusceptibilitytestinginpatientsreceivingtuberculosistreatment
AT mendozaticonaa validationofmicroscopicobservationdrugsusceptibilitytestingforrapiddirectrifampicinandisoniaziddrugsusceptibilitytestinginpatientsreceivingtuberculosistreatment
AT caviedesl validationofmicroscopicobservationdrugsusceptibilitytestingforrapiddirectrifampicinandisoniaziddrugsusceptibilitytestinginpatientsreceivingtuberculosistreatment
AT mooredaj validationofmicroscopicobservationdrugsusceptibilitytestingforrapiddirectrifampicinandisoniaziddrugsusceptibilitytestinginpatientsreceivingtuberculosistreatment
AT drancourtm validationofmicroscopicobservationdrugsusceptibilitytestingforrapiddirectrifampicinandisoniaziddrugsusceptibilitytestinginpatientsreceivingtuberculosistreatment